Trials / Terminated
TerminatedNCT04447404
DUR-928 in Subjects With SARS-CoV-2 With Acute Lung, Liver or Kidney Injury
A Randomized, Double-Blind, Placebo Controlled Study to Evaluate Safety and Efficacy of DUR-928 in Subjects Infected With SARS-CoV-2 With Acute Lung, Liver or Kidney Injury
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- Durect · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Evaluate safety and efficacy of DUR-928 in treatment of acute organ failure in subjects infected with SARS-CoV-2
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DUR-928 | IV infusion |
| DRUG | Placebo | IV infusion |
Timeline
- Start date
- 2020-09-21
- Primary completion
- 2021-03-04
- Completion
- 2021-03-04
- First posted
- 2020-06-25
- Last updated
- 2022-08-05
- Results posted
- 2022-08-05
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04447404. Inclusion in this directory is not an endorsement.